Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 499-504

  Sakkinen, Pamela A ^a   Cushman, Mary ^a,b   Psaty, Bruce M ^c   Rodriguez, Beatriz ^d   Boineau, Robin ^e   Kuller, Lewis H ^f   Tracy, Russell P ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f NONE

Author keywords

Blood coagulation; Diabetes; Elderly; Fibrinolysis; Myocardial infarction

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8C; FIBRINOGEN; INSULIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; THROMBIN;

AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0033050104     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.499     Document Type: Article

References (40)

1. Folsom A, Wu K, Rosamond W, Sharrett A, Chambless L. Hemostatic factors and incidence of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1996;93(suppl I):I-622. Abstract.
2. Thompson S, Kienast J, Pyke S, Haverkate F, van de Loo J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
3. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati M, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb. 1993;13:1412-1417.
4. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
5. Juhan-Vague I, Alessi M, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
6. Ridker P, Hennekens C, Cerskus A, Stampfer M. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 1994; 90:2236-2240.
7. Cushman M, Kuller L, Psaty B, Lemaitre R, Macy E, Sharrett AR, Tracy RP. D-dimer level in prediction of incident cardiovascular disease events in the elderly. Circulation. 1996;93(suppl I):I-457. Abstract.
8. Bachmann F. In: Colman R, Hirsh J, Marder V, Salzman E, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: JB Lippincott Co; 1994:1592-1622.
9. Cushman M, Lemaitre R, Kuller L, Psaty B, Macy E, Sharrett A, Tracy R. Fibrinolytic activation markers predict myocardial infarction in the elderly: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:493-498.
10. National Center for Health Statistics: Advance Report of Final Mortality Statistics, 1987. Hyattsville, Md: Public Health Service; 1989.
11. Fried L, Borhani N, Enright P, Furberg C, Gardin J, Kronmal R, Kuller L, Manolio T, Mittelmark M, Newman A, O'Leary D, Psaty B, Rautaharju P, Tracy R, Weiler P, for the CHS Research Group. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
12. Curb J, Petrovitch H, Rodriguez B. Fourth examination. In: Kagan A, ed. The Honolulu Heart Program: An Epidemiologic Study of Coronary Heart Disease and Stroke. Amsterdam, Netherlands: Harwood Academic Press; 1996.
13. Tell G, Fried L, Hermanson B, Manolio T, Newman A, Borhani N. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358-366.
14. O'Leary D, Polak J, Wolfson S, Bond M, Bommer W, Sheth S, Psaty B, Sharrett A, Manolio T, for CHS Investigators. Use of sonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke. 1991;22:1155-1163.
15. Gardin J, Wong N, Bommer W, Klopfenstein H, Smith V, Tabatznik B, Siscovick D, Lobodzinski S, Anton-Culver H, Manolio T. Echocardiographic design of a multi-center investigation of free-living elderly subjects: the Cardiovascular Health Study. J Am Soc Echocardiogr. 1992;5: 63-72.
16. Newman A, Siscovick D, Manolio T, Polak J, Fried L, Borhani N, Wolfson S, for the CHS Investigators. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation. 1993;88: 837-845.
17. Worth R, Kagan A. Ascertainment of men of Japanese ancestry in Hawaii through World War II Selective Service registration. J Chronic Dis. 1970;23:389-397.
18. Cushman M, Cornell E, Howard P, Bovill E, Tracy R. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41:264-270.
19. Mykkanen L, Haffner S, Ronnemaa T, Bergman R, Laakso M. Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. Am J Epidemiol 1997;146:315-321.
20. Reaven G. Role of insulin resistance in human disease. Diabetes. 1988; 37:1595-1607.
21. Stern M. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med. 1996;124:110-116.
22. Haffner S. Risk factors for non-insulin-dependent diabetes mellitus. J Hypertens. 1995;13(suppl):S73-S76.
23. Tracy R, Bovill E, Stump D, Lin T, Gomol T, Collen D, Mann K. Reduction of in vitro artifact during blood collection in TIMI II. Blood. 1988;78(suppl 1):376. Abstract.
24. DeClerck P, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost. 1987;58:1024-1029.
25. Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-α-2-antiplasmin complex in human plasma: application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost. 1986;56: 124-127.
26. DeClerck P, Alessi M, Verstrecken M, Kruithof E, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood. 1988;71:220-225.
27. DeClerck P, Verstrecken M, Collen D. Measurement of different forms of plasminogen activator inhibitor 1 (PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays. Fibrinolysis. 1990;4:132-133.
28. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost. 1985;54:684-697.
29. Macy E, Hayes T, Tracy R. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin Chem. 1997;43:52-58.
30. Wong W, Eaton D, Berloui A, Fendly B, Hass P. A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a). Clin Chem. 1990;36:192-197.
31. Diagnostica Stago. ST4 Operator's Manual. Parsippany, NJ: American Bioproducts; 1992.
32. Cushman M, Psaty B, Macy E, Bovill E, Cornell E, Kuller L, Tracy R. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol. 1996;16: 1163-1169.
33. Kuller L, Shemanski L, Psaty B, Borhani N, Gardin J, Haan M, O'Leary D, Savage P, Tell G, Tracy R. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation. 1995;92:720-726.
34. Cushman M, Cornell E, Macy E, Psaty B, Tracy R. Correlates of the fibrin fragment D-dimer, a measure of fibrinolysis, in an elderly cohort free of prevalent cardiovascular disease. Circulation. 1995;92(suppl I):I-624. Abstract.
35. Tracy R, Lemaitre R, Psaty B, Ives D, Evans R, Cushman M, Meilahn E, Kuller L. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
36. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
37. Robson S, Shephard E, Kirsch R. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1B, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol. 1994;86:322-326.
38. Ridker P, Vaughan D, Stampfer M, Manson J, Hennekens C. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
39. Calles-Escandon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel B. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr. 1996;64:7-11.
40. Juhan-Vague I, Alessi M. PAI-1, obesity, insulin resistance and risk of cardiovascular disease. Thromb Haemost. 1997;78:656-660.